Genentech Reports Interim Phase III Sefaxersen Data in IgAN

Interim Phase III IMAgINATION data showed investigational sefaxersen cut proteinuria 43.1% versus placebo at 37 weeks in adults with IgA nephropathy receiving optimized standard care. The 95% confidence interval was 32.5–52.0; P<0.0001. Safety was consistent with prior studies, with no new signals.